LeMaitre Vascular (NASDAQ:LMAT) Downgraded to Hold at StockNews.com

StockNews.com lowered shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a research note published on Saturday.

Several other research analysts also recently weighed in on LMAT. Roth Mkm restated a buy rating and issued a $100.00 target price on shares of LeMaitre Vascular in a research note on Friday, May 31st. JMP Securities upped their target price on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a market outperform rating in a research note on Friday, May 3rd. Stifel Nicolaus upgraded shares of LeMaitre Vascular from a hold rating to a buy rating and upped their target price for the company from $59.00 to $75.00 in a research note on Friday, April 26th. Roth Capital upgraded shares of LeMaitre Vascular to a strong-buy rating in a research note on Friday, May 31st. Finally, Barrington Research upped their target price on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an outperform rating in a research note on Friday, May 3rd. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $77.57.

LeMaitre Vascular Stock Up 1.1 %

LMAT opened at $81.50 on Friday. LeMaitre Vascular has a 52-week low of $44.27 and a 52-week high of $84.15. The company has a 50 day moving average of $74.63 and a two-hundred day moving average of $65.69. The company has a market cap of $1.83 billion, a P/E ratio of 53.97, a P/E/G ratio of 2.46 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The company had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. During the same period in the previous year, the firm earned $0.27 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 13.6% on a year-over-year basis. Research analysts anticipate that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th were paid a dividend of $0.16 per share. The ex-dividend date was Wednesday, May 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.79%. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 68,906 shares of the stock in a transaction on Monday, May 6th. The shares were sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the sale, the chief executive officer now directly owns 2,133,428 shares of the company’s stock, valued at $161,500,499.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 8,000 shares of the stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $75.30, for a total transaction of $602,400.00. Following the sale, the chief executive officer now directly owns 2,079,128 shares of the company’s stock, valued at $156,558,338.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 68,906 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the sale, the chief executive officer now directly owns 2,133,428 shares in the company, valued at $161,500,499.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 87,431 shares of company stock valued at $6,627,520. Company insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Large investors have recently modified their holdings of the company. Envestnet Asset Management Inc. increased its holdings in shares of LeMaitre Vascular by 24.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 195,983 shares of the medical instruments supplier’s stock worth $10,677,000 after acquiring an additional 38,958 shares during the period. Ranger Investment Management L.P. increased its holdings in shares of LeMaitre Vascular by 1.5% in the 4th quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock worth $51,794,000 after acquiring an additional 13,681 shares during the period. Vanguard Group Inc. increased its holdings in shares of LeMaitre Vascular by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,510,567 shares of the medical instruments supplier’s stock worth $82,296,000 after acquiring an additional 33,500 shares during the period. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of LeMaitre Vascular in the 4th quarter worth about $8,837,000. Finally, Congress Asset Management Co. MA increased its holdings in shares of LeMaitre Vascular by 17.0% in the 4th quarter. Congress Asset Management Co. MA now owns 594,672 shares of the medical instruments supplier’s stock worth $33,754,000 after acquiring an additional 86,293 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.